|
GB1591490A
(en)
*
|
1977-08-04 |
1981-06-24 |
Abbott Lab |
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate
|
|
US4188390A
(en)
*
|
1977-11-05 |
1980-02-12 |
Pfizer Inc. |
Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
|
|
FR2421888A1
(fr)
*
|
1978-02-06 |
1979-11-02 |
Synthelabo |
Amides d'alkylene-diamines et leur application en therapeutique
|
|
US4197301A
(en)
*
|
1978-10-16 |
1980-04-08 |
Allergan Pharmaceuticals, Inc. |
Topical ophthalmic use of Prazosin
|
|
US4287341A
(en)
*
|
1979-11-01 |
1981-09-01 |
Pfizer Inc. |
Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
|
|
DK121080A
(da)
*
|
1979-04-25 |
1980-10-26 |
Pfizer |
Fremgangsmaade til fremstilling af 2-piperazinoquinazolinderivater
|
|
EP0022481A1
(en)
*
|
1979-06-21 |
1981-01-21 |
Mitsubishi Yuka Pharmaceutical Co., Ltd. |
5,6-Alkylenepyrimidine derivatives, processes for preparing the same and pharmaceutical compositions
|
|
HU180708B
(en)
*
|
1979-10-11 |
1983-04-29 |
Chinoin Gyogyszer Es Vegyeszet |
Process for preparing new 1,2,4-oxadiazine derivatives
|
|
US4351940A
(en)
*
|
1980-03-03 |
1982-09-28 |
Pfizer Inc. |
Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines
|
|
US4367335A
(en)
*
|
1981-08-03 |
1983-01-04 |
Mead Johnson & Company |
Thiazolidinylalkylene piperazine derivatives
|
|
DE3346675A1
(de)
*
|
1983-12-23 |
1985-07-04 |
Beiersdorf Ag, 2000 Hamburg |
Substituierte 1-(4-amino-6,7-dialkoxy-chinazolinyl)-4- cyclohexenyl-derivate des piperazins und homopiperazins, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen und zwischenprodukte
|
|
FI79107C
(fi)
*
|
1984-06-25 |
1989-11-10 |
Orion Yhtymae Oy |
Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.
|
|
CA1307786C
(en)
*
|
1984-12-14 |
1992-09-22 |
Keiichi Yokoyama |
Quinazoline derivatives and antihypertensive preparations containing same as effective components
|
|
EP0237608B1
(de)
*
|
1986-03-21 |
1992-01-29 |
HEUMANN PHARMA GMBH & CO |
Kristalline, wasserfreie Sigma -Form von 2-[4-(2-Furoyl-(2-piperazin)-1-yl]-4-amino-6,7-dimethoxychinazolinhydrochlorid und Verfahren zu ihrer Herstellung
|
|
YU70890A
(en)
*
|
1989-04-21 |
1992-05-28 |
Egyt Gyogyszervegyeszeti Gyar |
Process for obtaining quinazoline derivatives
|
|
JPH03286800A
(ja)
*
|
1990-04-03 |
1991-12-17 |
Gunze Ltd |
衣類の折畳み装置
|
|
US5212176A
(en)
*
|
1990-06-29 |
1993-05-18 |
Abbott Laboratories |
R(+)-terazosin
|
|
IL101243A
(en)
*
|
1991-03-20 |
1999-12-22 |
Merck & Co Inc |
Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
|
|
CA2077252C
(en)
*
|
1992-08-31 |
2001-04-10 |
Khashayar Karimian |
Methods of making ureas and guanidines, and intermediates therefor
|
|
US5294615A
(en)
*
|
1993-04-29 |
1994-03-15 |
Abbott Laboratories |
Terazosin polymorph and pharmaceutical composition
|
|
US5412095A
(en)
*
|
1993-04-29 |
1995-05-02 |
Abbott Laboratories |
Terazosin monohydrochloride and processes and intermediate for its production
|
|
IT1270993B
(it)
*
|
1994-03-18 |
1997-05-26 |
Recordati Chem Pharm |
Derivati chinzolilamminici attivi come alfa-antagonisti
|
|
US5504207A
(en)
*
|
1994-10-18 |
1996-04-02 |
Abbott Laboratories |
Process and intermediate for the preparation of terazosin hydrochloride dihydrate
|
|
EP0853479A4
(en)
*
|
1995-09-29 |
2001-04-11 |
Merck & Co Inc |
ALPHA 1b ADRENERGIC RECEPTOR ANTAGONISTS
|
|
US5587377A
(en)
*
|
1995-10-24 |
1996-12-24 |
Invamed, Inc. |
Terazosin crystalline polymorph and pharmaceutical compositions thereof
|
|
DE19546573A1
(de)
*
|
1995-12-13 |
1997-06-19 |
Uetikon Chemie Gmbh |
Kristallines Polymorph von Terazosin-Hydrochlorid, sowie Verfahren zu seiner Herstellung
|
|
US6177430B1
(en)
|
1997-03-27 |
2001-01-23 |
Pfizer Inc |
Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
|
|
CA2173408C
(en)
*
|
1996-04-03 |
2001-09-04 |
K.S. Keshava Murthy |
Process for the manufacture of intermediates suitable to make doxazosin,terazosin, prazosin, tiodazosin and related antihypertensive medicines
|
|
US5952003A
(en)
*
|
1996-08-01 |
1999-09-14 |
Novartis Corporation |
Terazosin capsules
|
|
IT1286790B1
(it)
*
|
1996-11-29 |
1998-07-17 |
Alfa Chem Ital |
Processo per la produzione della forma i del terazosin monocloridrato anidro
|
|
IT1286789B1
(it)
*
|
1996-11-29 |
1998-07-17 |
Alfa Chem Ital |
Processo per la produzione della forma i del terazosin monocloridato anidro
|
|
GB9700504D0
(en)
*
|
1997-01-11 |
1997-02-26 |
Pfizer Ltd |
Pharmaceutical compounds
|
|
US6248888B1
(en)
*
|
1997-11-14 |
2001-06-19 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of terazosin hydrochloride dihydrate
|
|
HUP0104493A3
(en)
|
1998-09-30 |
2002-12-28 |
Takeda Pharmaceutical |
Drugs for improving vesical excretory strength
|
|
US20020065286A1
(en)
*
|
2000-08-21 |
2002-05-30 |
Davies Michael John |
Treatment of wounds
|
|
WO2003079972A2
(en)
|
2002-02-22 |
2003-10-02 |
New River Parmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
|
US20020091129A1
(en)
*
|
2000-11-20 |
2002-07-11 |
Mitradev Boolell |
Treatment of premature ejaculation
|
|
US20030060513A1
(en)
*
|
2001-09-27 |
2003-03-27 |
Arneric Stephen P. |
Pharmaceutical composition
|
|
GB0130219D0
(en)
*
|
2001-12-18 |
2002-02-06 |
Pfizer Ltd |
Compounds for the treatment of sexual dysfunction
|
|
US20030229001A1
(en)
*
|
2002-01-31 |
2003-12-11 |
Pfizer Inc. |
Treatment of male sexual dysfunction
|
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
|
US7323462B2
(en)
*
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
|
EP1572173B1
(en)
|
2002-12-13 |
2010-04-28 |
Warner-Lambert Company LLC |
Alpha-2-delta ligand to treat lower urinary tract symptoms
|
|
CA2451267A1
(en)
*
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
|
PA8597401A1
(es)
*
|
2003-03-14 |
2005-05-24 |
Pfizer |
Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
|
|
US20040220186A1
(en)
*
|
2003-04-30 |
2004-11-04 |
Pfizer Inc. |
PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
|
|
US20050065158A1
(en)
*
|
2003-07-16 |
2005-03-24 |
Pfizer Inc. |
Treatment of sexual dysfunction
|
|
US20050059744A1
(en)
*
|
2003-09-12 |
2005-03-17 |
Allergan, Inc. |
Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
|
|
US20050058696A1
(en)
*
|
2003-09-12 |
2005-03-17 |
Allergan, Inc. |
Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
|
|
JP5165242B2
(ja)
|
2003-09-12 |
2013-03-21 |
アラーガン、インコーポレイテッド |
疼痛およびα２アドレナリン受容体が関与する他の状態の処置のための方法および組成物
|
|
US7291640B2
(en)
*
|
2003-09-22 |
2007-11-06 |
Pfizer Inc. |
Substituted triazole derivatives as oxytocin antagonists
|
|
US20050267096A1
(en)
*
|
2004-05-26 |
2005-12-01 |
Pfizer Inc |
New indazole and indolone derivatives and their use pharmaceuticals
|
|
US20050288270A1
(en)
*
|
2004-05-27 |
2005-12-29 |
Pfizer Inc |
New aminopyridine derivatives and their use as pharmaceuticals
|
|
CA2500676A1
(en)
*
|
2005-03-11 |
2006-09-11 |
Apotex Pharmachem Inc. |
Preparation of acid addition salts of amine bases by solid phase-gas phase reactions
|
|
CA2602383A1
(en)
*
|
2005-03-21 |
2006-09-28 |
Pfizer Limited |
Substituted triazole derivatives as oxytocin antagonists
|
|
US7618972B2
(en)
*
|
2005-03-21 |
2009-11-17 |
Pfizer Inc |
Substituted triazole derivatives as oxytocin antagonists
|
|
US20060264442A1
(en)
*
|
2005-05-18 |
2006-11-23 |
Allergan, Inc. |
Methods for the treatment of ocular and neurodegenerative conditions in a mammal
|
|
US20100222365A1
(en)
*
|
2005-08-10 |
2010-09-02 |
Pfizer Inc |
Substituted triazole deriviatives as oxytocin antagonists
|
|
US20070086958A1
(en)
*
|
2005-10-14 |
2007-04-19 |
Medafor, Incorporated |
Formation of medically useful gels comprising microporous particles and methods of use
|
|
US20070161791A1
(en)
*
|
2006-01-09 |
2007-07-12 |
Narsimha Reddy Penthala |
Process for the preparation of terazosin hydrocloride dihydrate
|
|
CN101190890B
(zh)
|
2006-11-30 |
2011-04-27 |
江苏豪森药业股份有限公司 |
5-[(2r)-[2-[2-[2-(2,2,2-三氟乙氧基)苯氧基]乙基]氨基]丙基]-2-甲氧基苯磺酰胺
|
|
WO2009007984A2
(en)
*
|
2007-07-11 |
2009-01-15 |
Hetero Drugs Limited |
An improved process for erlotinib hydrochloride
|
|
CN103739596A
(zh)
*
|
2013-12-10 |
2014-04-23 |
刘磊 |
用于心脑血管疾病的喹唑啉衍生物
|
|
US11224572B1
(en)
|
2020-08-17 |
2022-01-18 |
Novitium Pharma LLC |
Stable oral liquid composition of terazosin
|
